Dynavax falls on updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.65 (14%) to $16.70 Thursday after reporting updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating its SD-101 plus PD-1 inhibitor Keytruda pembrolizumab to treat unresectable stage IIIc or IV melanoma. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

SD-101 is an immunostimulatory sequence (ISS)-based second-generation type C toll-like receptor 9 agonist...